Elisabeth A. Minthorn

Publications by Year

Research Areas

Melanoma and MAPK Pathways, Synthesis and biological activity, PI3K/AKT/mTOR signaling in cancer, Synthesis of Tetrazole Derivatives, Cancer therapeutics and mechanisms

Most-Cited Works

• → Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)(2012)608 cited
• → GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition(2011)594 cited
• → Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity(2013)426 cited
• → Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity(2008)296 cited
• → Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia(2021)262 cited
• → Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys(2001)239 cited
• → Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development(2013)226 cited
• → Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction(2014)206 cited
• → Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase(2008)155 cited
• → Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor(2014)143 cited